Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


29.03.2021

3 Ann Surg Oncol
5 BMC Cancer
1 BMJ
9 Br J Cancer
2 Breast Cancer
1 Breast Cancer (Dove Med Press)
4 Breast Cancer Res
14 Breast Cancer Res Treat
3 Breast J
1 Cancer Lett
1 Cancer Res
5 Clin Breast Cancer
2 Clin Cancer Res
1 Curr Treat Options Oncol
4 Eur J Cancer
3 Eur Radiol
2 Int J Oncol
1 J Biol Chem
2 J Clin Oncol
2 J Natl Cancer Inst
2 J Surg Oncol
2 N Engl J Med
1 Nat Rev Clin Oncol
6 NPJ Breast Cancer
4 Oncogene
2 Oncol Rep
5 PLoS One
1 Radiology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Surg Oncol

  1. MOHAN SC, Walcott-Sapp S, Lee MK, Srour MK, et al
    Alterations in Breast Cancer Biomarkers Following Neoadjuvant Therapy.
    Ann Surg Oncol. 2021 Mar 21. pii: 10.1245/s10434-021-09814.
    PubMed         Abstract available

  2. TANG A, Cohan CM, Beattie G, Cureton EL, et al
    Patients Older 65 Years With Early Breast Cancer Prefer Intraoperative Radiation as a Locoregional Treatment Choice.
    Ann Surg Oncol. 2021 Mar 9. pii: 10.1245/s10434-021-09618.
    PubMed         Abstract available

  3. METCALFE KA, Eisen A, Poll A, Candib A, et al
    Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result.
    Ann Surg Oncol. 2021 Mar 24. pii: 10.1245/s10434-021-09855.
    PubMed         Abstract available


    BMC Cancer

  4. SANDVEI MS, Opdahl S, Valla M, Lagiou P, et al
    The association of women's birth size with risk of molecular breast cancer subtypes: a cohort study.
    BMC Cancer. 2021;21:299.
    PubMed         Abstract available

  5. YUAN Q, Hou J, He Y, Liao Y, et al
    Minimize the extent and morbidity of axillary dissection for node-positive breast cancer patients: implementation of axillary lymph node dissection based on breast lymphatics level.
    BMC Cancer. 2021;21:293.
    PubMed         Abstract available

  6. JAYASINGHE R, Fernando A, Jayarajah U, Seneviratne S, et al
    Post treatment quality of life among Sri Lankan women with breast cancer.
    BMC Cancer. 2021;21:305.
    PubMed         Abstract available

  7. ALOMRAN R, White M, Bruce M, Bressel M, et al
    Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR).
    BMC Cancer. 2021;21:303.
    PubMed         Abstract available

  8. FALCICCHIO C, Di Lallo D, Fabi A, Bonucci A, et al
    Use of rehabilitation pathways in women with breast cancer in the first 12 months of the disease: a retrospective study.
    BMC Cancer. 2021;21:311.
    PubMed         Abstract available


    BMJ


  9. Effect of screening by clinical breast examination on breast cancer incidence and mortality after 20 years: prospective, cluster randomised controlled trial in Mumbai.
    BMJ. 2021;372:n738.
    PubMed        


    Br J Cancer

  10. AMBROISE G, Yu TT, Zhang B, Kacal M, et al
    Systematic analysis reveals a functional role for STAMBPL1 in the epithelial-mesenchymal transition process across multiple carcinomas.
    Br J Cancer. 2020;123:1164-1177.
    PubMed         Abstract available

  11. DE MUNCK L, Siesling S, Fracheboud J, den Heeten GJ, et al
    Impact of mammographic screening and advanced cancer definition on the percentage of advanced-stage cancers in a steady-state breast screening programme in the Netherlands.
    Br J Cancer. 2020;123:1191-1197.
    PubMed         Abstract available

  12. PEDROZA DA, Rajamanickam V, Subramani R, Bencomo A, et al
    Progesterone receptor membrane component 1 promotes the growth of breast cancers by altering the phosphoproteome and augmenting EGFR/PI3K/AKT signalling.
    Br J Cancer. 2020;123:1326-1335.
    PubMed         Abstract available

  13. MILIGY IM, Toss MS, Shiino S, Oni G, et al
    The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ.
    Br J Cancer. 2020;123:1513-1520.
    PubMed         Abstract available

  14. LI YY, Gao LJ, Zhang YX, Liu SJ, et al
    Bisphosphonates and risk of cancers: a systematic review and meta-analysis.
    Br J Cancer. 2020;123:1570-1581.
    PubMed         Abstract available

  15. FARVID MS, Spence ND, Rosner BA, Willett WC, et al
    Post-diagnostic coffee and tea consumption and breast cancer survival.
    Br J Cancer. 2021 Mar 24. pii: 10.1038/s41416-021-01277.
    PubMed         Abstract available

  16. KROL I, Schwab FD, Carbone R, Ritter M, et al
    Detection of clustered circulating tumour cells in early breast cancer.
    Br J Cancer. 2021 Mar 24. pii: 10.1038/s41416-021-01327.
    PubMed         Abstract available

  17. RAKHA EA, Miligy IM, Quinn CM, Provenzano E, et al
    Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio >/=2.0, HER2 copy number <4.0 signals/cell) cases.
    Br J Cancer. 2021 Mar 24. pii: 10.1038/s41416-021-01351.
    PubMed         Abstract available

  18. DAVE RV, Kim B, Courtney A, O'Connell R, et al
    Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase of the B-MaP-C study.
    Br J Cancer. 2021 Mar 25. pii: 10.1038/s41416-020-01234.
    PubMed         Abstract available


    Breast Cancer

  19. NAHVIJOU A, Safari H, Ameri H
    Correction to: Psychometric properties of the SF-6Dv2 in an Iranian breast cancer population.
    Breast Cancer. 2021 Mar 26. pii: 10.1007/s12282-021-01243.
    PubMed        

  20. DU L, Tao X, Shen X
    Human umbilical cord mesenchymal stem cell-derived exosomes inhibit migration and invasion of breast cancer cells via miR-21-5p/ZNF367 pathway.
    Breast Cancer. 2021 Mar 26. pii: 10.1007/s12282-021-01218.
    PubMed         Abstract available


    Breast Cancer (Dove Med Press)

  21. DUCHE H, Tsegay AT, Tamirat KS
    Identifying Risk Factors of Breast Cancer Among Women Attending Selected Hospitals of Addis Ababa City: Hospital-Based Unmatched Case-Control Study.
    Breast Cancer (Dove Med Press). 2021;13:189-197.
    PubMed         Abstract available


    Breast Cancer Res

  22. YU J, Qin B, Moyer AM, Sinnwell JP, et al
    Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.
    Breast Cancer Res. 2021;23:41.
    PubMed        

  23. DEMICHELE A, Cristofanilli M, Brufsky A, Liu X, et al
    Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.
    Breast Cancer Res. 2021;23:37.
    PubMed         Abstract available

  24. GALARDI F, De Luca F, Biagioni C, Migliaccio I, et al
    Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
    Breast Cancer Res. 2021;23:38.
    PubMed         Abstract available

  25. GATTI G, Betts C, Rocha D, Nicola M, et al
    High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer.
    Breast Cancer Res. 2021;23:40.
    PubMed         Abstract available


    Breast Cancer Res Treat

  26. HO PJ, Dorajoo R, Ivankovic I, Ong SS, et al
    DNA methylation and breast cancer-associated variants.
    Breast Cancer Res Treat. 2021 Mar 26. pii: 10.1007/s10549-021-06185.
    PubMed         Abstract available

  27. AHN SG, Kim SK, Shepherd JH, Cha YJ, et al
    Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer.
    Breast Cancer Res Treat. 2021 Mar 26. pii: 10.1007/s10549-021-06193.
    PubMed         Abstract available

  28. LEONE J, Freedman RA, Lin NU, Tolaney SM, et al
    Tumor subtypes and survival in male breast cancer.
    Breast Cancer Res Treat. 2021 Mar 26. pii: 10.1007/s10549-021-06182.
    PubMed         Abstract available

  29. OPPONG BA, Obeng-Gyasi S, Relation T, Adams-Campbell L, et al
    Call to action: breast cancer screening recommendations for Black women.
    Breast Cancer Res Treat. 2021 Mar 26. pii: 10.1007/s10549-021-06207.
    PubMed         Abstract available

  30. GOEL AK, Zamre V, Hari S
    Variation in pathological complete response in HER2-positive breast cancers with intrinsic subtypes assessed by PAM50 testing: secondary analysis from NSABP B-41 trial.
    Breast Cancer Res Treat. 2020;183:489-490.
    PubMed        

  31. SHEEAN P, Matthews L, Visotcky A, Banerjee A, et al
    Every Day Counts: a randomized pilot lifestyle intervention for women with metastatic breast cancer.
    Breast Cancer Res Treat. 2021 Mar 19. pii: 10.1007/s10549-021-06163.
    PubMed         Abstract available

  32. IBRAGIMOVA KIE, Geurts SME, Croes S, Erdkamp F, et al
    Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry.
    Breast Cancer Res Treat. 2021 Mar 20. pii: 10.1007/s10549-021-06178.
    PubMed         Abstract available

  33. KUEMMEL S, Tondini CA, Abraham J, Nowecki Z, et al
    Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
    Breast Cancer Res Treat. 2021 Mar 21. pii: 10.1007/s10549-021-06145.
    PubMed         Abstract available

  34. MASUDA N, Bando H, Yamanaka T, Kadoya T, et al
    Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
    Breast Cancer Res Treat. 2021 Mar 25. pii: 10.1007/s10549-021-06184.
    PubMed         Abstract available

  35. WANG C, Tong F, Cao Y, Liu P, et al
    Long-term follow-up results of fluorescence and blue dye guided sentinel lymph node biopsy in early breast cancer.
    Breast Cancer Res Treat. 2021 Mar 24. pii: 10.1007/s10549-021-06196.
    PubMed         Abstract available

  36. CHEN I, Botty Van den Bruele AM, Gillespie EF, Mueller BA, et al
    Salvage of locally recurrent breast cancer with repeat breast conservation using 45 Gy hyperfractionated partial breast re-irradiation.
    Breast Cancer Res Treat. 2021 Mar 26. pii: 10.1007/s10549-021-06206.
    PubMed         Abstract available

  37. MCGEE S, Alzahrani M, Vandermeer L, Cole K, et al
    Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey.
    Breast Cancer Res Treat. 2021 Mar 23. pii: 10.1007/s10549-021-06147.
    PubMed         Abstract available

  38. THOMAS S, Kabir M, Butcher BE, Chou S, et al
    Interobserver concordance in visual assessment of Ki67 immunohistochemistry in surgical excision specimens from patients with lymph node-negative breast cancer.
    Breast Cancer Res Treat. 2021 Mar 22. pii: 10.1007/s10549-021-06188.
    PubMed         Abstract available

  39. BUCKLEY E, Elder E, McGill S, Kargar ZS, et al
    Breast cancer treatment and survival differences in women in remote and socioeconomically disadvantaged areas, as demonstrated by linked data from New South Wales (NSW), Australia.
    Breast Cancer Res Treat. 2021 Mar 21. pii: 10.1007/s10549-021-06170.
    PubMed         Abstract available


    Breast J

  40. KIZILTAN G, Bozdogan N, Ozaslan C
    Breast cancer metastasis into thyroid papillary microcarcinoma: A case report.
    Breast J. 2021 Mar 10. doi: 10.1111/tbj.14219.
    PubMed         Abstract available

  41. LAROIYA I, Irrinki S, Subbhiah Nagaraj S, Sakaray YR, et al
    Triple-negative breast cancer and factors affecting disease-free survival-Experience from a tertiary care center in India.
    Breast J. 2021 Mar 21. doi: 10.1111/tbj.14227.
    PubMed        

  42. JAMALUDDIN MF, Abraham AG, Menon G, Nakatsui T, et al
    Recurrent radiation recall dermatitis 40 years after radiation therapy for breast cancer.
    Breast J. 2021 Mar 24. doi: 10.1111/tbj.14212.
    PubMed         Abstract available


    Cancer Lett

  43. SHI Y, Zhang Y, Ran F, Liu J, et al
    Let-7a-5p inhibits triple-negative breast tumor growth and metastasis through GLUT12-mediated warburg effect.
    Cancer Lett. 2020;495:53-65.
    PubMed         Abstract available


    Cancer Res

  44. LI CI, Flanagan MR, Tang MC, Porter PL, et al
    Bisphosphonate Use and Breast Cancer Risk among Women with Ductal Carcinoma In Situ.
    Cancer Res. 2021 Mar 24. pii: 0008-5472.CAN-20-4100.
    PubMed         Abstract available


    Clin Breast Cancer

  45. KOZAK MM, von Eyben R, Gutkin PM, Vemuri M, et al
    Locoregional and Distant Outcomes in Women With cT1-3N1 Breast Cancer Treated With Neoadjuvant Chemotherapy With or Without Adjuvant Radiotherapy.
    Clin Breast Cancer. 2021 Feb 26. pii: S1526-8209(21)00050.
    PubMed         Abstract available

  46. DAILY K, Douglas E, Romitti PA, Thomas A, et al
    Epidemiology of De Novo Metastatic Breast Cancer.
    Clin Breast Cancer. 2021 Jan 31. pii: S1526-8209(21)00029.
    PubMed         Abstract available

  47. LAILLER G, Memoli V, Le Bihan Benjamin C, Ben Diane MK, et al
    Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.
    Clin Breast Cancer. 2021 Jan 13. pii: S1526-8209(21)00019.
    PubMed         Abstract available

  48. MA S, Guo C, Sun C, Han T, et al
    Aspirin Use and Risk of Breast Cancer: A Meta-analysis of Observational Studies from 1989 to 2019.
    Clin Breast Cancer. 2021 Feb 17. pii: S1526-8209(21)00047.
    PubMed         Abstract available

  49. SALVATORE S, Nappi RE, Casiraghi A, Ruffolo AF, et al
    Microablative Fractional CO2 Laser for Vulvovaginal Atrophy in Women With a History of Breast Cancer: A Pilot Study at 4-week Follow-up.
    Clin Breast Cancer. 2021 Feb 23. pii: S1526-8209(21)00007.
    PubMed         Abstract available


    Clin Cancer Res

  50. NARAYAN P, Osgood CL, Singh H, Chiu HJ, et al
    FDA Approval Summary: Fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer.
    Clin Cancer Res. 2021 Mar 22. pii: 1078-0432.CCR-20-4557.
    PubMed         Abstract available

  51. LI CI, Zhang Y, Cieslik M, Wu YM, et al
    Cancer cell-intrinsic and immunological phenotypes determine clinical outcomes in basal-like breast cancer.
    Clin Cancer Res. 2021 Mar 22. pii: 1078-0432.CCR-20-3890.
    PubMed         Abstract available


    Curr Treat Options Oncol

  52. ISAACS J, Anders C, McArthur H, Force J, et al
    Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Curr Treat Options Oncol. 2021;22:38.
    PubMed         Abstract available


    Eur J Cancer

  53. JEONG JH, Kim JE, Ahn JH, Jung KH, et al
    Corrigendum to "Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study [Eur J Canc 144 (2021) 341-350].
    Eur J Cancer. 2021 Mar 7. pii: S0959-8049(21)00071.
    PubMed        

  54. MICHAELSON-COHEN R, Gabizon-Peretz S, Armon S, Srebnik-Moshe N, et al
    Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
    Eur J Cancer. 2021;148:95-102.
    PubMed         Abstract available

  55. VILLEGAS SL, Nekljudova V, Pfarr N, Engel J, et al
    Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Eur J Cancer. 2021;148:159-170.
    PubMed         Abstract available

  56. QUINTANA A, Peg V, Prat A, Moline T, et al
    Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer.
    Eur J Cancer. 2021;148:134-145.
    PubMed         Abstract available


    Eur Radiol

  57. MILOS RI, Pipan F, Kalovidouri A, Clauser P, et al
    The Kaiser score reliably excludes malignancy in benign contrast-enhancing lesions classified as BI-RADS 4 on breast MRI high-risk screening exams.
    Eur Radiol. 2020;30:6052-6061.
    PubMed         Abstract available

  58. ZHANG Z, Wang W, Wang X, Yu X, et al
    Breast-specific gamma imaging or ultrasonography as adjunct imaging diagnostics in women with mammographically dense breasts.
    Eur Radiol. 2020;30:6062-6071.
    PubMed         Abstract available

  59. YOON JH, Kim EK, Kim GR, Han K, et al
    Comparing recall rates following implementation of digital breast tomosynthesis to synthetic 2D images and digital mammography on women with breast-conserving surgery.
    Eur Radiol. 2020;30:6072-6079.
    PubMed         Abstract available


    Int J Oncol

  60. MU H, Zhang W, Qiu Y, Tao T, et al
    miRNAs as potential markers for breast cancer and regulators of tumorigenesis and progression (Review).
    Int J Oncol. 2021;58.
    PubMed         Abstract available

  61. KANG J, Zhong Y, Tian W, Li J, et al
    A novel anthraquinonequinazoline hybrid 7B blocks breast cancer metastasis and EMT via targeting EGFR and Rac1.
    Int J Oncol. 2021;58.
    PubMed         Abstract available


    J Biol Chem

  62. CHRISTENSEN EM, Bogner AN, Vandekeere A, Tam GS, et al
    In crystallo screening for proline analog inhibitors of the proline cycle enzyme PYCR1.
    J Biol Chem. 2020;295:18316-18327.
    PubMed         Abstract available


    J Clin Oncol

  63. WEINSTEIN SP, Korhonen K, Cirelli C, Schnall MD, et al
    Abbreviated Breast Magnetic Resonance Imaging for Supplemental Screening of Women With Dense Breasts and Average Risk.
    J Clin Oncol. 2020;38:3874-3882.
    PubMed         Abstract available

  64. ARAOYE EF, Stearns V, Aguh C
    Considerations for the Use of Scalp Cooling Devices in Black Patients.
    J Clin Oncol. 2020;38:3575-3576.
    PubMed        


    J Natl Cancer Inst

  65. HOULAHAN KE
    Do Breast Cancer Risk Scores Work for You?
    J Natl Cancer Inst. 2021 Mar 25. pii: 6189097. doi: 10.1093.
    PubMed        

  66. DU Z, Gao G, Adedokun B, Ahearn T, et al
    Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry.
    J Natl Cancer Inst. 2021 Mar 26. pii: 6189099. doi: 10.1093.
    PubMed         Abstract available


    J Surg Oncol

  67. YAMAMOTO T, Kageyama T, Sakai H, Fuse Y, et al
    Thoracoacromial artery and vein as main recipient vessels in deep inferior epigastric artery perforator (DIEP) flap transfer for breast reconstruction.
    J Surg Oncol. 2021;123:1232-1237.
    PubMed         Abstract available

  68. VARTANIAN ED, Lo AY, Hershenhouse KS, Jacob L, et al
    The role of neurotization in autologous breast reconstruction: Can reconstruction restore breast sensation?
    J Surg Oncol. 2021;123:1215-1231.
    PubMed         Abstract available


    N Engl J Med

  69. COPUR MS
    Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    N Engl J Med. 2021;384:1176.
    PubMed        

  70. BURSTEIN HJ
    Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Reply.
    N Engl J Med. 2021;384:1176-1177.
    PubMed        


    Nat Rev Clin Oncol

  71. GYAWALI B, Kesselheim AS
    FDA approval standards for anticancer agents - lessons from two recent approvals in breast cancer.
    Nat Rev Clin Oncol. 2021 Mar 25. pii: 10.1038/s41571-021-00504.
    PubMed        


    NPJ Breast Cancer

  72. MODI ND, Tan JQE, Rowland A, Koczwara B, et al
    The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data.
    NPJ Breast Cancer. 2021;7:30.
    PubMed         Abstract available

  73. ALMEKINDERS MMM, Schaapveld M, Thijssen B, Visser LL, et al
    Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ.
    NPJ Breast Cancer. 2021;7:31.
    PubMed         Abstract available

  74. KALRA M, Tong Y, Jones DR, Walsh T, et al
    Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer.
    NPJ Breast Cancer. 2021;7:29.
    PubMed         Abstract available

  75. ALHALABI O, Soomro Z, Sun R, Hasanov E, et al
    Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases.
    NPJ Breast Cancer. 2021;7:28.
    PubMed         Abstract available

  76. BAZAN JG, Jhawar SR, Stover D, Park KU, et al
    De-escalation of radiation therapy in patients with stage I, node-negative, HER2-positive breast cancer.
    NPJ Breast Cancer. 2021;7:33.
    PubMed         Abstract available

  77. DECENSI A, Johansson H, Helland T, Puntoni M, et al
    Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial.
    NPJ Breast Cancer. 2021;7:34.
    PubMed         Abstract available


    Oncogene

  78. LIANG Y, Song X, Li Y, Su P, et al
    Correction: circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer.
    Oncogene. 2021 Mar 25. pii: 10.1038/s41388-021-01750.
    PubMed        

  79. WANG X, Feng M, Xiao T, Guo B, et al
    BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer.
    Oncogene. 2021 Mar 25. pii: 10.1038/s41388-021-01756.
    PubMed         Abstract available

  80. HUTCHINSON SA, Websdale A, Cioccoloni G, Roberg-Larsen H, et al
    Liver x receptor alpha drives chemoresistance in response to side-chain hydroxycholesterols in triple negative breast cancer.
    Oncogene. 2021 Mar 19. pii: 10.1038/s41388-021-01720.
    PubMed         Abstract available

  81. WANG YH, Chan YT, Hung TH, Hung JT, et al
    Transmembrane and coiled-coil domain family 3 (TMCC3) regulates breast cancer stem cell and AKT activation.
    Oncogene. 2021 Mar 19. pii: 10.1038/s41388-021-01729.
    PubMed         Abstract available


    Oncol Rep

  82. LI M, Liu Y, Deng Y, Pan L, et al
    Therapeutic potential of endogenous hydrogen sulfide inhibition in breast cancer (Review).
    Oncol Rep. 2021;45.
    PubMed         Abstract available

  83. KIM JM, Park J, Noh EM, Song HK, et al
    Bruton's agammaglobulinemia tyrosine kinase (Btk) regulates TPAinduced breast cancer cell invasion via PLCgamma2/PKCbeta/NFkappaB/AP1dependent matrix metalloproteinase9 activation.
    Oncol Rep. 2021;45.
    PubMed         Abstract available


    PLoS One

  84. UMAMAHESWARAN G, Kadambari D, Muthuvel SK, Kumar NAN, et al
    Polymorphisms of T- cell leukemia 1A gene loci are not related to the development of adjuvant letrozole-induced adverse events in breast cancer.
    PLoS One. 2021;16:e0247989.
    PubMed         Abstract available

  85. LOURO J, Roman M, Posso M, Vazquez I, et al
    Developing and validating an individualized breast cancer risk prediction model for women attending breast cancer screening.
    PLoS One. 2021;16:e0248930.
    PubMed         Abstract available

  86. OSAPOETRA LO, Chan W, Tran W, Kolios MC, et al
    Comparison of methods for texture analysis of QUS parametric images in the characterization of breast lesions.
    PLoS One. 2020;15:e0244965.
    PubMed         Abstract available

  87. TOYODA Y, Tabuchi T, Hama H, Morishima T, et al
    Trends in clinical stage distribution and screening detection of cancer in Osaka, Japan: Stomach, colorectum, lung, breast and cervix.
    PLoS One. 2020;15:e0244644.
    PubMed         Abstract available

  88. GRANQVIST V, Holmgren C, Larsson C
    Induction of interferon-beta and interferon signaling by TRAIL and Smac mimetics via caspase-8 in breast cancer cells.
    PLoS One. 2021;16:e0248175.
    PubMed         Abstract available


    Radiology

  89. KIM SY, Cho N, Choi Y, Lee SH, et al
    Factors Affecting Pathologic Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer: Development and Validation of a Predictive Nomogram.
    Radiology. 2021 Mar 23:203871. doi: 10.1148/radiol.2021203871.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: